Literature DB >> 7902770

Differential vulnerability to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine of dopaminergic and cholinergic neurons in the monkey mesopontine tegmentum.

M T Herrero1, E C Hirsch, F Javoy-Agid, J A Obeso, Y Agid.   

Abstract

Parkinson's disease is characterized by a loss of dopaminergic neurons in the substantia nigra and, in the most severe cases, by degeneration of mesopontine cholinergic neurons. In a monkey model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine we report that, despite a severe loss of dopaminergic neurons, in the mesopontine tegmentum cholinergic neurons are preserved in the same region. This suggests that the loss of mesopontine cholinergic neurons in parkinsonian patients may represent an end-stage degenerative process, the cause of which may be independent of the mechanism of dopaminergic cell death.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7902770     DOI: 10.1016/0006-8993(93)90088-5

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  10 in total

Review 1.  Role of the pedunculopontine nucleus in controlling gait and sleep in normal and parkinsonian monkeys.

Authors:  C Karachi; Chantal Francois
Journal:  J Neural Transm (Vienna)       Date:  2017-01-13       Impact factor: 3.575

2.  Reduced noradrenergic innervation of ventral midbrain dopaminergic cell groups and the subthalamic nucleus in MPTP-treated parkinsonian monkeys.

Authors:  Gunasingh Jeyaraj Masilamoni; Olivia Groover; Yoland Smith
Journal:  Neurobiol Dis       Date:  2016-12-30       Impact factor: 5.996

3.  Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease.

Authors:  Carine Karachi; David Grabli; Frédéric A Bernard; Dominique Tandé; Nicolas Wattiez; Hayat Belaid; Eric Bardinet; Annick Prigent; Hans-Peter Nothacker; Stéphane Hunot; Andreas Hartmann; Stéphane Lehéricy; Etienne C Hirsch; Chantal François
Journal:  J Clin Invest       Date:  2010-07-12       Impact factor: 14.808

4.  Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.

Authors:  Gunasingh J Masilamoni; James W Bogenpohl; David Alagille; Kristen Delevich; Gilles Tamagnan; John R Votaw; Thomas Wichmann; Yoland Smith
Journal:  Brain       Date:  2011-07       Impact factor: 13.501

5.  Cortical Serotonergic and Catecholaminergic Denervation in MPTP-Treated Parkinsonian Monkeys.

Authors:  Gunasingh Jeyaraj Masilamoni; Allison Weinkle; Stella M Papa; Yoland Smith
Journal:  Cereb Cortex       Date:  2022-04-20       Impact factor: 4.861

Review 6.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

7.  Sleep disorders in Parkinsonian macaques: effects of L-dopa treatment and pedunculopontine nucleus lesion.

Authors:  Hayat Belaid; Joëlle Adrien; Elodie Laffrat; Dominique Tandé; Carine Karachi; David Grabli; Isabelle Arnulf; Stewart D Clark; Xavier Drouot; Etienne C Hirsch; Chantal François
Journal:  J Neurosci       Date:  2014-07-02       Impact factor: 6.167

8.  Gait disorders in parkinsonian monkeys with pedunculopontine nucleus lesions: a tale of two systems.

Authors:  David Grabli; Carine Karachi; Emmanuelle Folgoas; Morgane Monfort; Dominique Tande; Stewart Clark; Olivier Civelli; Etienne C Hirsch; Chantal François
Journal:  J Neurosci       Date:  2013-07-17       Impact factor: 6.167

9.  Nonhuman Primate Models of Neurodegenerative Disorders.

Authors:  Marina E Emborg
Journal:  ILAR J       Date:  2017-12-01

10.  Increased Expression of Alpha-, Beta-, and Gamma-Synucleins in Brainstem Regions of a Non-Human Primate Model of Parkinson's Disease.

Authors:  Sandra Duperrier; Analia Bortolozzi; Véronique Sgambato
Journal:  Int J Mol Sci       Date:  2022-08-02       Impact factor: 6.208

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.